CRISPR-Cas9 gene editing has been around not even 4 years, and people are avidly discussing its promises and perils (see “The Public and the Gene Editing Revolution” in today’s New England Journal of Medicine). That’s great. But

Second Gene Therapy Nears Approval in Europe: Lessons for CRISPR?
Posted April 14, 2016 by